Xencor, Inc.

David F Carmichael

John R Desjarlais

Gregory Alan Lazar

Sher Bahadur Karki

Seung Yup Chu

Bao-lu Chen

Lori Kunkel

Philip W Hammond

Gregory L Moore

Jonathan Zalevsky

John O Richards

David Szymkowski

Paul Michael Steed

Bao-Lu Chen

An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.

Optimized anti-CD30 antibodies

The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.

Modified FC molecules

An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.

The invention relates to a pharmaceutical composition comprising a variant TNF-&#x3b1; protein that inhibits the activity of soluble TNF-&#x3b1; while substantially maintaining the activity of transmembrane TNF-&#x3b1; a buffer and a tonicity agent wherein said composition has a pH from approximately 5.0 to 8.0.

Pharmaceutical compositions for the treatment of TNF-&#x3b1; related disorders

Growing community of inventors

Monrovia, CA, United States of America

David F Carmichael